期刊
JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 145, 期 2, 页码 198-201出版社
JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1016/j.jphs.2020.12.003
关键词
Dual orexin receptor antagonist (DORA); Noradrenalin transporter (Net); Hippocampus
资金
- Investigator-Initiated Studies Program of Merck Sharpe Dohme Corp.
The orexinergic system is crucial in regulating proper sleep/wake maintenance, and the dual orexin receptor antagonist (DORA) is commonly used for treating insomnia symptoms. DORA treatment significantly impacts the expression levels of monoamine-related genes in the hippocampus, contributing to the regulation of noradrenalin-related gene expression in the central nervous system.
The orexinergic system plays a significant role in regulating proper sleep/wake maintenance. Dual orexin receptor antagonist (DORA) is widely prescribed for insomnia symptoms. The antagonist acts on orexin 1 and 2 receptors located in certain brain areas, including the locus coeruleus and dorsal raphe. Nevertheless, its effects on monoamine-related gene expression remain unclear. Here, we measured the expression levels of monoamine-related genes in DORA-treated mice. DORA treatment significantly affected overall levels of noradrenalin transporter/monoamine oxidases A mRNA expression in the hippocampus. Our findings suggest that DORA contributes to noradrenalin-related gene expression regulation in the central nervous system. (c) 2020 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据